Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. Bms-986165
1. Bms-986165
2. 1609392-27-9
3. Tyk2-in-4
4. Bms986165
5. Deucravacitinib [usan]
6. N0a21n6rau
7. 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-n-(trideuteriomethyl)pyridazine-3-carboxamide
8. Deucravacitinib (usan)
9. Sotyktu
10. Unii-n0a21n6rau
11. Deucravacitinib [inn]
12. Deucravacitinib [jan]
13. Chembl4435170
14. Deucravacitinib [who-dd]
15. Schembl20520348
16. Gtpl10432
17. Ex-a3154
18. Bdbm50507816
19. Mfcd31715455
20. Nsc825520
21. S8879
22. Tyk2-in-4(bms986165)
23. Who 11342
24. At18623
25. Nsc-825520
26. Compound 11 [pmid: 31318208}
27. Ncgc00687789-01
28. Ac-31543
29. Hy-117287
30. Cs-0065044
31. D11817
32. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)-
33. 3-pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)n-(methyl-d3)-
34. 6-((cyclopropylcarbonyl)amino)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(2h3)methyl-3-pyridazine-carboxamide
35. 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-((2h3)methyl)pyridazine-3-carboxamide
36. 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl]amino]-n-(methyl-d3)-3-pyridazinecarboxamide
Molecular Weight | 425.5 g/mol |
---|---|
Molecular Formula | C20H22N8O3 |
XLogP3 | 1.2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 425.20031683 g/mol |
Monoisotopic Mass | 425.20031683 g/mol |
Topological Polar Surface Area | 136 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 648 |
Isotope Atom Count | 3 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of psoriasis
Treatment of Systemic Lupus Erythematosus (SLE)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AA - Selective immunosuppressants
L04AA56 - Deucravacitinib
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Deucravacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deucravacitinib, including repackagers and relabelers. The FDA regulates Deucravacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deucravacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Deucravacitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Deucravacitinib supplier is an individual or a company that provides Deucravacitinib active pharmaceutical ingredient (API) or Deucravacitinib finished formulations upon request. The Deucravacitinib suppliers may include Deucravacitinib API manufacturers, exporters, distributors and traders.
click here to find a list of Deucravacitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Deucravacitinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Deucravacitinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Deucravacitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Deucravacitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Deucravacitinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Deucravacitinib suppliers with NDC on PharmaCompass.
Deucravacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deucravacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deucravacitinib GMP manufacturer or Deucravacitinib GMP API supplier for your needs.
A Deucravacitinib CoA (Certificate of Analysis) is a formal document that attests to Deucravacitinib's compliance with Deucravacitinib specifications and serves as a tool for batch-level quality control.
Deucravacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Deucravacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deucravacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Deucravacitinib EP), Deucravacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deucravacitinib USP).
LOOKING FOR A SUPPLIER?